Passage Bio, Inc. (PASG)
NASDAQ: PASG · Real-Time Price · USD
0.3500
-0.0310 (-8.14%)
Mar 31, 2025, 1:39 PM EDT - Market open

Passage Bio Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2019 - 2018
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2019 - 2018
Selling, General & Admin
24.9941.5845.5460.0630.11
Upgrade
Research & Development
40.1861.4283.75117.6781.79
Upgrade
Operating Expenses
65.17103129.29177.73111.9
Upgrade
Operating Income
-65.17-103-129.29-177.73-111.9
Upgrade
Interest & Investment Income
4.35.62.33.121.3
Upgrade
Other Non Operating Income (Expenses)
1.330.73-0.03--
Upgrade
EBT Excluding Unusual Items
-59.53-96.67-127.03-174.61-110.6
Upgrade
Merger & Restructuring Charges
---6.1--
Upgrade
Gain (Loss) on Sale of Investments
----2.78-0.63
Upgrade
Asset Writedown
-5.23-5.39---
Upgrade
Pretax Income
-64.77-102.06-136.13-185.39-112.23
Upgrade
Net Income
-64.77-102.06-136.13-185.39-112.23
Upgrade
Net Income to Common
-64.77-102.06-136.13-185.39-112.23
Upgrade
Shares Outstanding (Basic)
6055545339
Upgrade
Shares Outstanding (Diluted)
6055545339
Upgrade
Shares Change (YoY)
10.34%0.58%2.03%38.14%811.60%
Upgrade
EPS (Basic)
-1.07-1.86-2.50-3.48-2.91
Upgrade
EPS (Diluted)
-1.07-1.86-2.50-3.48-2.91
Upgrade
Free Cash Flow
-47.99-78.41-120.48-144.52-81.67
Upgrade
Free Cash Flow Per Share
-0.79-1.43-2.21-2.71-2.12
Upgrade
EBITDA
-62.09-99.28-125.62-176.19-111.1
Upgrade
D&A For EBITDA
3.083.723.681.540.8
Upgrade
EBIT
-65.17-103-129.29-177.73-111.9
Upgrade
Updated Mar 4, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q